摘要
目的评价沙利度胺联合CTOD(环磷酰胺、吡柔比星、长春新碱、地塞米松)化疗方案治疗多发性骨髓瘤22例的疗效和不良反应。方法22例患者均给予小剂量沙利度胺联合化疗,沙利度胺的剂量为50～200mg/d,环磷酰胺(CTX)500～600mg/m2×1d,吡柔比星(THP)20mg/m2×(2～3)d;长春新碱(VCR)2mg/m2×1d,地塞米松(Dex)10～15mg/m2×(5～7)d;每2～3月重复,有效可继续化疗2～4次。结果患者一疗程总有效率为90.90%(完全缓解率为4.54%,部分缓解率86.36%),主要不良反应为骨髓抑制,白细胞和血小板分别在化疗后第5～12天、第5～14天降到最低值,外周血象一般在11～15d恢复正常。不良反应不明显,无1例患者因化疗发生不良反应而死亡。结论沙利度胺联合CTOD化疗方案治疗多发性骨髓瘤的较理想方案。
Objective To evaluate the effects and toxicities of a regimen of therapy by means of thalidomide （TLD） combined with Cyclophosphamide （ CTX）, Pirarubicin （ THP）, Vincristine Sulfate （ VCR）, and Dexamethasone （Dex） for 22 patients with multiple myeloma（MM）. Methods 22 MM sufferers were selected to receive the above curative therapy. The close of thalidomide was 50-200mg/day ,The patients were treated with CTX 500-600rag/ m^2 × 1 d, THP 20mg/m^2 × （2-3）d; and VCR 2 mg/m^2 × ld,Dex 10 15 mg/m^2 × （5-7）d. The regiments were repeated every 2 or 3 months and each patient got 2 to 4 cycles treatment. Results After one period treatment using the thalidomide with CTOD regimen, the total effective rate is 90.90% （CR 4.54% and PR86.36 %）in multiple myeloma. The chief adverse side effect of the thalidomide with CTOD regimen was the severe sustaining bone narrow sup pression. The counts of the leukocyte and thrombotocyte reduced to the lowest rate after the treatment of 5 to 12 days and 5 to14 days. It took 11to15days for recovery. The other adverse side effects are not obvious and no patients died or stopped the treatment because of the adverse side effects. Conclusion The thalidomide with CTOD regimen can achieve perfect results in treating the patients with MM.
出处
《检验医学与临床》
CAS
2010年第7期591-592,共2页
Laboratory Medicine and Clinic
关键词
沙利度胺
化疗
多发性骨髓瘤
thalidomide
chemotherapy
multiple myeloma
